Exercise of Options and Issue of Equity

e-Therapeutics plc

24 January 2024

 

e-therapeutics plc

("e-therapeutics" or the "Company")

Exercise of Options and Issue of Equity

London, UK, 24 January 2024 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a company integrating computational power and biological data to discover life-transforming RNAi medicines, announces that it has allotted 400,000 new ordinary shares of 0.1p each in the Company (the "New Ordinary Shares") following the exercise of 400,000 employee share options at an exercise price of 0.1p per share.

Application has been made to AIM for the admission of the New Ordinary Shares to trading on AIM ("Admission") and Admission is expected to occur at 8:00 a.m. on or around 31 January 2024. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.

Following Admission, the total number of ordinary shares in the Company with voting rights in issue will be 584,335,487. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation.

For further information, please contact:

Enquiries:

e-therapeutics plc
Ali Mortazavi, CEO Timothy Bretherton, CFO	Tel: [phone] www.etherapeutics.co.uk
SP Angel Corporate Finance LLP	Tel: [phone]
Nominated Adviser and Broker Matthew Johnson/Harry Davies-Ball (Corporate Finance) Vadim Alexandre/Rob Rees (Corporate Broking)

About e-therapeutics plc

e-therapeutics plc ("ETX") integrates computational power and biology information to discover life-transforming RNAi medicines. The Company's technology uses computation to capture and model human biology, identify novel targets, and develop RNAi medicines against those targets that can be rapidly progressed to the clinic. 

ETX's proprietary HepNet™ platform enables the generation and analysis of biological network models, providing a novel and mechanistic approach to drug discovery. This approach explicitly considers the true complexity of biology to make more reliable predictions from large complex data sets and ETX's proprietary hepatocyte knowledgebase - the world's most comprehensive and integrated hepatocyte-centric data resource.  The Company generates, prioritises, and tests millions of hypotheses in silico to identify better therapeutic targets with higher confidence.

GalOmic™, ETX's proprietary RNAi platform, enables targeted delivery to hepatocytes in the liver and the specific silencing of novel disease-associated genes, identified by HepNet™. The focus on hepatocytes offers the opportunity to tackle a wide variety of diseases.  The liver is a highly metabolically active organ which performs a key role in many biological processes and vital functions crucial for human health. ETX's GalOmic™ constructs have demonstrated compelling in vivo performance in terms of depth of gene silencing and duration of action.

The Company is progressing a pipeline of first-in-class RNAi candidates across a variety of therapeutic areas with high unmet need, including preclinical programs in cardiometabolic and metabolic diseases, haemophilia, and other undisclosed indications. ETX has also partnered with biopharma companies such as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational network biology approach across a diverse range of drug discovery projects.

The Company is based in London, UK and listed on the Alternative Investment Market of the London Stock Exchange ("AIM"), with ticker symbol ETX.

 

END